Get the Stockscreener App
17.08
0.99%
-0.17
Pre-market:
17.30
0.22
+1.29%
Personalis Inc stock is traded at $17.08, with a volume of 2.17M.
It is down -0.99% in the last 24 hours and up +44.99% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$17.25
Open:
$17.18
24h Volume:
2.17M
Relative Volume:
0.53
Market Cap:
$1.82B
Revenue:
$64.52M
Net Income/Loss:
$-95.55M
P/E Ratio:
-16.80
EPS:
-1.0169
Net Cash Flow:
$-84.65M
1W Performance:
+8.03%
1M Performance:
+44.99%
6M Performance:
+89.15%
1Y Performance:
+250.00%
1-Day Range:
$16.84
$17.50
1-Week Range:
$15.91
$18.89
52-Week Range:
$4.6524
$18.89
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, NTRA, A, IDXX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
17.08 | 1.80B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
633.71 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.36 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.45 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
155.08 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IDXX
Idexx Laboratories Inc
|
553.44 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Tempus AI Shares Jump $3 Billion After Moderna Victory Boosts Value of $1.5 Billion Personalis Stake - TechStock²
AMERIPRISE FINANCIAL INC Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value - GuruFocus
Why Tempus AI (TEM) Is Up 22.8% After Buying the Platform Behind a Key mRNA Cancer Win - simplywall.st
Deep Track Capital, LP Trims Personalis Inc (PSNL) Stake -- Shar - GuruFocus
Personalis secures new Million Veteran Program task order - TipRanks
Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP - TradingView
Personalis wins up to $18.3M VA MVP task order, cumulative VA awards reach $243.3M - TradingView
Personalis (NASDAQ: PSNL) wins Million Veteran Program task order—how big is it? - Stock Titan
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight - Stocktwits
Tempus soars on coattails of Moderna/Merck cancer vaccine - Crain's Chicago Business
Personalis stock reaches 52-week high at 16.42 USD - Investing.com
Personalis stock reaches 52-week high at 16.42 USD By Investing.com - Investing.com Canada
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM) - Seeking Alpha
Personalis | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Personalis Inc : PSNL - 247wallst.com
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant - Yahoo Finance
Tempus AI Jumps 24% as Merck-Moderna mRNA Vaccine Win Lifts Personalis Deal - finance.biggo.com
TEM Stock Dips As Tempus AI Bets $1.5B On Personalis - StocksToTrade
Personalis Inc. (PSNL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes - timothysykes.com
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
What Personalis (PSNL)'s Rising Revenue But Deepening Losses Means For Shareholders - webull.com
Tempus Is Buying Cancer-Testing Partner Personalis for $1.5 Billion - RamaOnHealthcare
Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock - Stock Titan
Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership - Stock Titan
Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL - MarketBeat
Personalis, Inc. (PSNL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Personalis Inc (PSNL) Shares Fall 3.2% -- What GF Score of 53 Te - GuruFocus
Personalis, Inc. $PSNL Stock Holdings Lifted by Dimensional Fund Advisors LP - MarketBeat
Personalis (PSNL) Is Up 6.1% After Q2 Revenue Rises But Losses DeepenWhat's Changed - webull.com
TEM Surges Into $1.5B MRD Deal As Stock Pulls Back - StocksToTrade
Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes - StocksToTrade
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Personalis Inc (PSNL) Stock News Today - TradingKey
Cancer Detection Test Receives Regulatory Marking for Use in Great Britain - Clinical Lab Products
Growth Potential For Personalis, Inc. (PSNL): A Look At Its 30% Revenue Surge - DirectorsTalk Interviews
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lake Street Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $16.25 - Moomoo
Personalis Reports Second Quarter 2026 Results and Recent Highlights - biospace.com
Is Personalis Inc (PSNL) Significantly Overvalued Even After Q2 Revenue of $22.4 Million? GF Score: 59/100 - GuruFocus
Personalis : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Personalis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Personalis, Inc. Q2 2026: Revenue $22.36M, EPS $(0.30) — 10-Q Summary - TradingView
Earnings Flash (PSNL) Personalis, Inc. Reports Q2 Revenue $22.4M, vs. FactSet Est of $16.7M - marketscreener.com
Personalis Q2 revenue rises 30% to $22.4 million - Quiver Quantitative
Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage - TradingView
Personalis (NASDAQ: PSNL) posts larger loss and strikes Tempus cash-stock merger - Stock Titan
Personalis: Q2 Earnings Snapshot - marketscreener.com
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chen Richard | President and CMO |
Jul 15 '26 |
Sale |
15.15 |
100,000 |
1,515,000 |
173,880 |
0.58%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):